The battle for post-Recanemab has heated up. Among other things, we analyze the current status and prospects for the development of tau inhibitors, which aim to become a fundamental therapeutic agent.
https://miyata-bio.net/column/0000375/
The commercialization of two anti-Aβ antibody products that inhibit the deterioration of early-stage Alzheimer's disease is in sight. However, this is only the first technological breakthrough. A second race had begun with changes in therap
The patent cliff is truly frightening. Humira, the world's largest biopharmaceutical, which had been doing well in the U.S. market, has finally fall off the market.
https://miyata-bio.net/column/0000372/
Finally, commercialization of pathway drug discovery is underway. It is an era in which combination drugs can be rationally discovered according to disease pathways.
https://miyata-bio.net/column/0000370/
The second wave of commercialization for nucleic acid drugs
The second wave of practical application of nucleic acid medicine has arrived. Ligand-binding nucleic acid drugs are its engine. We take an inside look at this innovation.
https://miyata-bio.net/column/0000368/
The second wave of commercialization for nucleic acid drugs
The secrets of its successful IPO on its second attempt.
The final part of the report focuses on the smart listing strategy taken by the CFO and the post-IPO stock price formation strategy. It is a good reference.
Chordia Therapeutic, the company that buried the urban legend of the "100 Equivalen
The secrets of its successful IPO on its second attempt.
Chordia Therapeutic, the company that buried the urban legend of the "CAP OF 10B yen at IPO" of biotech ventures on the TSE Growth Market, reveals the secrets of its successful IPO on its second try.
https://miyata-bio.net/column/0000367/
